These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26345518)

  • 1. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
    Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
    Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
    Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
    Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
    Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
    Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia.
    Semsei AF; Erdelyi DJ; Ungvari I; Csagoly E; Hegyi MZ; Kiszel PS; Lautner-Csorba O; Szabolcs J; Masat P; Fekete G; Falus A; Szalai C; Kovacs GT
    Cell Biol Int; 2012 Jan; 36(1):79-86. PubMed ID: 21929509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
    Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
    J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
    Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
    J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
    Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
    J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
    Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
    J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
    Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
    N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
    Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
    N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
    Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
    J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL.
    Krajinovic M; Robaey P; Chiasson S; Lemieux-Blanchard E; Rouillard M; Primeau M; Bournissen FG; Moghrabi A
    Pharmacogenomics; 2005 Apr; 6(3):293-302. PubMed ID: 16013960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors.
    Caru M; Corbin D; Périé D; Lemay V; Delfrate J; Drouin S; Bertout L; Krajinovic M; Laverdière C; Andelfinger G; Sinnett D; Curnier D
    Clin Res Cardiol; 2019 Sep; 108(9):1000-1008. PubMed ID: 30778669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
    Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
    Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
    Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
    Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL.
    Zaruma-Torres F; Lares-Asseff I; Reyes-Espinoza A; Loera-Castañeda V; Chairez-Hernández I; Sosa-Macías M; Galaviz-Hernández C; Almanza-Reyes H
    Drug Metab Pers Ther; 2015 Sep; 30(3):195-201. PubMed ID: 26353179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.